Award of share options

RNS Number : 3455T

Ergomed plc

03 July 2018

 

PRESS RELEASE

Ergomed award of share options to Directors and Company Secretary

London, UK - 3 July 2018: Ergomed plc, (LSE:ERGO) ("Ergomed" or the "Company")  a company focused on providing specialised services to the pharmaceutical industry, today announces that the following LTIP (Long Term Investment Plan) awards have been made to newly-appointed CFO Stuart Jackson, COO Jan Petracek, and General Counsel and Company Secretary Sanja Juric.

The awards consist of share options over the Company's ordinary shares having a nominal value of 1 pence each (the "Options") with an exercise price of 1 pence per share.  Of the total, 50% of the Options will vest after three years and are not subject to performance criteria. The remaining 50% will vest based on total shareholder return over the three year vesting period with a minimum of 15 per cent. per annum. Once vested the options will be exercisable until 1 July 2028.

Director / Executive	Award of Options	Resulting interest in options	Current shareholding in the Company
Stuart Jackson, Chief Financial Officer	400,000	400,000	1,845
Jan Petracek, Chief Operations Officer	400,000	450,000	418,006
Sanja Juric, General Counsel and Company Secretary *	25,000	175,000	Nil

* Sanja Juric also holds 150,000 options over shares owned by Dr Miroslav Reljanovic.

In total 825,000 Options were granted yesterday, representing 1.8 per cent. of the issued share capital.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	1)   Stuart Jackson 2)   Jan Petracek 3)   Sanja Juric
2	Reason for the notification
a)	Position/status	1)   Chief Financial Officer 2)   Chief Operations Officer 3)   General Counsel and Company Secretary
b)	Initial notification /Amendment	1)   Initial Notification 2)   Initial Notification 3)   Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Ergomed Plc
b)	Legal Entity Identifier	213800BVS8I9VMC1AP84
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of 1 pence each  GB00BN7ZCY67
b)	Nature of the transaction	Award of options
c)	Currency	GBP
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		1)   Nil	400,000
		2)   Nil	450,000
		3)   Nil	175,000
e)	Aggregated information - Aggregated volume - Price - Aggregated total	1) 400,000 ordinary shares of 1 pence each, nil consideration 2) 450,000 ordinary shares of 1 pence each, nil consideration 3) 175,000 ordinary shares of 1 pence each, nil consideration
f)	Date of the transaction	03 July 2018
g)	Place of the transaction	Outside a trading venue

ENDS

Enquiries:

Ergomed plc	Tel: [phone]
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited	Tel: [phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
N+1 Singer	Tel: [phone]
Aubrey Powell (Joint Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Mary-Jane Elliott Ivar Milligan / Olivia Manser	[e-mail]
MC Services - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

END

 

 

MSCSSIEFEFASEDW